Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Director Anthony E. Maida III sold 7,250 shares of Spectrum Pharmaceuticals stock in a transaction on Monday, January 7th. The stock was sold at an average price of $10.00, for a total transaction of $72,500.00. Following the completion of the transaction, the director now directly owns 40,238 shares of the company’s stock, valued at $402,380. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
SPPI stock opened at $10.33 on Thursday. Spectrum Pharmaceuticals, Inc. has a 12 month low of $6.22 and a 12 month high of $25.29. The stock has a market cap of $1.04 billion, a P/E ratio of -9.65 and a beta of 2.56.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.10. Spectrum Pharmaceuticals had a negative net margin of 91.56% and a negative return on equity of 27.72%. The firm had revenue of $25.27 million during the quarter, compared to analysts’ expectations of $25.73 million. During the same period in the previous year, the company earned ($0.11) EPS. The firm’s revenue for the quarter was down 30.6% compared to the same quarter last year. As a group, analysts predict that Spectrum Pharmaceuticals, Inc. will post -0.9 earnings per share for the current year.
A number of equities analysts have commented on the stock. Zacks Investment Research reissued a “hold” rating on shares of Spectrum Pharmaceuticals in a research note on Friday, November 16th. ValuEngine cut shares of Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. BidaskClub raised shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. B. Riley dropped their price objective on shares of Spectrum Pharmaceuticals to $21.00 and set a “buy” rating for the company in a research note on Thursday, December 20th. Finally, TheStreet cut shares of Spectrum Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Wednesday, September 26th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $27.00.
TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4067789/spectrum-pharmaceuticals-inc-sppi-director-anthony-e-maida-iii-sells-7250-shares.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients.
Featured Article: What are the benefits of a balanced fund?
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.